TY - JOUR
T1 - Tissue-specific oncogenic activity of KRASA146T
AU - Poulin, Emily J.
AU - Bera, Asim K.
AU - Lu, Jia
AU - Lin, Yi Jang
AU - Strasser, Samantha Dale
AU - Paulo, Joao A.
AU - Huang, Tannie Q.
AU - Morales, Carolina
AU - Yan, Wei
AU - Cook, Joshua
AU - Nowak, Jonathan A.
AU - Brubaker, Douglas K.
AU - Joughin, Brian A.
AU - Johnson, Christian W.
AU - Destefanis, Rebecca A.
AU - Ghazi, Phaedra C.
AU - Gondi, Sudershan
AU - Wales, Thomas E.
AU - Iacob, Roxana E.
AU - Bogdanova, Lana
AU - Gierut, Jessica J.
AU - Li, Yina
AU - Engen, John R.
AU - Perez-Mancera, Pedro A.
AU - Braun, Benjamin S.
AU - Gygi, Steven P.
AU - Lauffenburger, Douglas A.
AU - Westover, Kenneth D.
AU - Haigis, Kevin M.
N1 - Funding Information:
We thank the staff at the structural biology laboratory at UT Southwestern Medical Center and at beamline 19ID of Advanced Photon Source for facilitating X-ray data collection and processing. Results are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, operated by the University of Chicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. This work was supported by grants from the NIH: R01CA178017 and R01CA195744 to K. Haigis; U01CA215798 to K. Haigis and D. Lauffenburger; R01CA173085 and P30CA082103 to B. Braun; and K01DK098285 to J. Paulo. This work was also supported by grants from the Cancer Research UK Grand Challenge and the Mark Foundation for Cancer Research (C5470/ A27144 to K. Haigis as a member of the SPECIFICANCER Team), the Department of Defense (W81XWH-16-1-0106 to K. Westover), and the Cancer Prevention and Research Institute of Texas (RP170373 to K. Westover). E. Poulin and J. Gierut were supported by postdoctoral fellowships from the American Cancer Society. Y. Lin was supported by a fellowship from the Landry Cancer Biology Consortium. S. Strasser was supported by a National Science Foundation Graduate Research Fellowship (grant no. 1122374). D. Brubaker was funded by a grant from Boehringer-Ingelheim as part of the SHINE program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Funding Information:
J.R. Engen reports receiving commercial research grants from Boehringer-Ingelheim and Novartis. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
© 2019, American Association for Cancer Research Inc.. All rights reserved.
PY - 2019/6
Y1 - 2019/6
N2 - KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor– induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.
AB - KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor– induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.
UR - http://www.scopus.com/inward/record.url?scp=85067213467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067213467&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-18-1220
DO - 10.1158/2159-8290.CD-18-1220
M3 - Article
C2 - 30952657
AN - SCOPUS:85067213467
SN - 2159-8274
VL - 9
SP - 738
EP - 755
JO - Cancer discovery
JF - Cancer discovery
IS - 6
ER -